TOP1 and melanoma: The DARs of I1‐DXd and I1‐MMAE were determined by HIC as 8 and 4, respectively (Supplement Figure S1G‐H), in consistency with clinical ADCs with the same linker and payload combination.[3, 13] I1‐DXd acts on melanoma cells via its DNA topoisomerase I inhibitor DXd payload whereas I1‐MMAE through microtubule inhibitor MMAE payload.